Interferon-inducible protein-10 as a marker to detect latent and active @entity378 in XXXX .

@entity1 @entity5 @entity9178 @entity310 @entity379 @entity371 @entity378 @entity309
SETTING: effective @entity378 ( @entity378 ) screening should be performed before anti- @entity5 necrosis factor alpha ( @entity310 ) treatment in @entity309 ( @entity309 ). The usefulness of the tuberculin skin test (TST) and QuantiFERON  - @entity378 Gold (QFT-G) for detecting @entity9178 ( @entity9178 ) is limited. OBJECTIVE: we tested the diagnostic performance of @entity379 ( @entity379 ) inducible protein 10 ( @entity371 ) and @entity379 for detecting @entity9178 in @entity309 patients receiving anti- @entity310 treatment. DESIGN: @entity371 levels were determined by enzyme-linked immunosorbent assay in 56 @entity309 @entity1 and 18 active @entity378 @entity1 . TST was performed using the Mantoux method and QFT-G was performed by measuring @entity379 levels in whole blood treated with @entity378 -specific antigens. RESULTS: twenty-four (42.9%) TST-positive @entity1 were defined as having @entity9178 . Significantly higher levels of baseline, early secretory antigenic target 6 (ESAT-6) and culture filtrate protein 10 (CFP-10) stimulated @entity371 were observed in active @entity378 @entity1 (median 209.9 pg/ml, 899.0 pg/ml and 880.2 pg/ml, respectively) and @entity309 @entity1 with @entity9178 (165.3 pg/ml, 904.4 pg/ml and 747.5 pg/ml, respectively), compared to those without @entity9178 (89.3 pg/ml, 579.4 pg/ml and 515.0 pg/ml, respectively). Baseline @entity371 has high sensitivity (83.3% and 100%) and medium specificity (67.9% and 59.6%), while ESAT-6-stimulated @entity371 has high sensitivity (87.5% and 100%) and specificity (85.7% and 71.2%) for detecting @entity9178 and @entity378 . The performance of @entity371 is superior to @entity379 for detecting @entity9178 (TST+) and active @entity378 . CONCLUSION: @entity371 may be used for detecting @entity9178 and as a potential biomarker to identify active @entity378 in @entity309 patients receiving anti- @entity310 treatment.
